Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-136960

Published: 2020

Journal Articles

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Andy C. Rawstron, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Shanna Maycock, BSc, MSc, Nichola Webster, Kristian Brock, PhD, Rebecca H. Boucher, BSc, MSc, PhD, Francesca Yates, PhD, Rebecca Jarvis, BSc, Surita Dalal, PhD, Ruth M. de Tute, PhD FRCPath, Paul Moss, MBBS, PhD FRCP, Donald Macdonald, MBChB, MD FRCP, PhD FCRPath, Piers Patten, MD PhD, Christopher Fegan, Andrew Pettitt, MA, MB BChir, PhD MRCP, MRCPath, Christopher P. Fox, MD PhD, Adrian Bloor, PhD FRCP, FRCPath, Oonagh Sheehy, MB BCh BAO, MRCP, FRCPath, Peter Hillmen, MBChB, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-136990

Published: 2020

Journal Articles

Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study

Blood (2017) 130 (Supplement 1): LBA-2.

https://doi.org/10.1182/blood.V130.Suppl_1.LBA-2.LBA-2

Published: 2017

Journal Articles

Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry

Hubert Schrezenmeier, Robert A Brodsky, MD, Petra Muus, MD, PhD, Monica Bessler, MD, PhD, Jeffrey Szer, MBBS, FRACP, Jaroslaw P Maciejewski, MD, PhD, FACP, Gérard Socié, Alvaro Urbano-Ispizua, MD, Yuzuru Kanakura, MD, PhD, Britta Hoechsmann, Wendell F Rosse, MD, Gus Khursigara, PhD, Anders Karnell, MD, PhD, Camille L Bedrosian, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 2241.

https://doi.org/10.1182/blood.V116.21.2241.2241

Published: 2010

Journal Articles

CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (<2%)

Andy C Rawstron, PhD, Chi Doughty, PhD, Ruth M de Tute, Fiona Bennett, Selina Denman, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Andrew Jack, PhD, MB

Blood (2010) 116 (21): 2002.

https://doi.org/10.1182/blood.V116.21.2002.2002

Published: 2010

Journal Articles

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

Blood (2010) 116 (21): 921.

https://doi.org/10.1182/blood.V116.21.921.921

Published: 2010

Journal Articles

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, Richard A Jones, Andy Rawstron, PhD, J Sheila, Paul Evans, Carter Anthony, Claire E. Dearden, MD, Estella Matutes, Andrew R. Pettitt, PhD, MRCPath, Daniel B. Kennedy, Sharon Barrans, Lisa Worrillow, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 922.

https://doi.org/10.1182/blood.V116.21.922.922

Published: 2010

Journal Articles

Long Term Treatment with Eculizumab In Paroxysmal Nocturnal Hemoglobinuria (PNH): Sustained Efficacy and Improved Survival

Richard J Kelly, MBChB, MRCP(UK), FRCPath, Anita Hill, MBChB, MRCP(UK), FRCPath, PhD, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Stephen John Richards, PhD, FRCPath, Louise M Arnold, RN, BSc, hons, Gemma L Valters, RN, BSc, hons, Matthew Cullen, MSc, Dena R Cohen, MSc, Walter M Gregory, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 639.

https://doi.org/10.1182/blood.V116.21.639.639

Published: 2010

Journal Articles

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

Michael Andreeff, MD, PhD, Kensuke Kojima, MD, PhD, Swaminathan Padmanabhan, MD, Roger Strair, MD, Mark Kirschbaum, MD, Peter Maslak, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, Susan O'Brien, Felipe Samaniego, Gautam Borthakur, MD, Marina Konopleva, MD, PhD, Lyubomir Vassilev, PhD, Gwen Nichols, MD

Blood (2010) 116 (21): 657.

https://doi.org/10.1182/blood.V116.21.657.657

Published: 2010

Journal Articles

Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Robert A Brodsky, MD, Carlos de Castro, III, MD, Hubert Schrezenmeier, MD, Professor, Antonio M. Risitano, MD, PhD, Joerg Schubert, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Ulrich Duehrsen, MD, Lucio Luzzatto, MD, FRCP, FRCPath, Petra Muus, MD, PhD, Jeffrey Szer, BMedSc, MBBS, FRACP, Gérard Socié, MD, PhD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 4237.

https://doi.org/10.1182/blood.V116.21.4237.4237

Published: 2010

Journal Articles

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Dena Cohen, Christopher F.E. Pocock, MD, PhD, Andy Rawstron, PhD, Walter M Gregory, Alex Smith, Emma Skinner, BSc, Anne Critchley, MB, BS, Donald Milligan, MD, FRCP, FRCPath, Claire E. Dearden, MD, Helen McCarthy, Chris Fegan, George A Follows, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 60.

https://doi.org/10.1182/blood.V116.21.60.60

Published: 2010

Journal Articles

Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry.

Petra Muus, MD, PhD, Jeffrey Szer, MBBS, FRACP, Hubert Schrezenmeier, MD, Professor, Robert A Brodsky, MD, Monica Bessler, MD, PhD, Gérard Socié, Alvaro Urbano-Ispizua, MD, Jaroslaw P Maciejewski, MD, PhD, FACP, Wendell F Rosse, MD, Yuzuru Kanakura, MD, PhD, Gus Khursigara, PhD, Anders Karnell, MD, PhD, Camille L Bedrosian, MD, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 1525.

https://doi.org/10.1182/blood.V116.21.1525.1525

Published: 2010

Journal Articles

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

Blood (2010) 116 (21): 1376.

https://doi.org/10.1182/blood.V116.21.1376.1376

Published: 2010

NARROW

Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

Ibrutinib and Obinutuzumab in CLL: MRD Responses Sustained for Several Years with Deepest MRD Depletion in Patients with >1 Year Prior Ibrutinib Exposure

Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study

Use of Blood Transfusions In Paroxysmal Nocturnal Hemoglobinuria Patients with and without Aplastic Anemia Enrolled In the Global PNH Registry

CD5-Negative Monoclonal B-Cell Lymphocytosis (MBL) Is Detectable In 9% of Adults Aged Over 40 but Phenotypes Associated with Clinically Common Non-Hodgkin Lymphomas Are Infrequent (<2%)

Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Long Term Treatment with Eculizumab In Paroxysmal Nocturnal Hemoglobinuria (PNH): Sustained Efficacy and Improved Survival

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

Long Term Safety and Efficacy of Sustained Eculizumab Treatment In Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCRN CLL207 Study of Alemtuzumab Consolidation In CLL: Final Response Assessment and Early Follow-up (on Behalf of the NCRI CLL Trials Sub-Group)

Evaluation of Paroxysmal Nocturnal Hemoglobinuria Disease Burden: The Patient's Perspective. A Report From the International PNH Registry.

Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only